全文获取类型
收费全文 | 984篇 |
免费 | 2篇 |
专业分类
化学工业 | 5篇 |
金属工艺 | 32篇 |
机械仪表 | 1篇 |
建筑科学 | 2篇 |
能源动力 | 2篇 |
轻工业 | 13篇 |
石油天然气 | 1篇 |
无线电 | 2篇 |
一般工业技术 | 1篇 |
冶金工业 | 925篇 |
自动化技术 | 2篇 |
出版年
2022年 | 1篇 |
2020年 | 1篇 |
2018年 | 1篇 |
2017年 | 1篇 |
2016年 | 1篇 |
2015年 | 2篇 |
2013年 | 5篇 |
2011年 | 3篇 |
2009年 | 3篇 |
2008年 | 2篇 |
2007年 | 7篇 |
2006年 | 4篇 |
2005年 | 2篇 |
2004年 | 2篇 |
2003年 | 3篇 |
2002年 | 6篇 |
2001年 | 2篇 |
1999年 | 22篇 |
1998年 | 307篇 |
1997年 | 149篇 |
1996年 | 116篇 |
1995年 | 68篇 |
1994年 | 52篇 |
1993年 | 39篇 |
1992年 | 6篇 |
1991年 | 16篇 |
1990年 | 22篇 |
1989年 | 24篇 |
1988年 | 29篇 |
1987年 | 13篇 |
1986年 | 13篇 |
1985年 | 5篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1981年 | 6篇 |
1980年 | 6篇 |
1978年 | 1篇 |
1977年 | 12篇 |
1976年 | 28篇 |
1964年 | 1篇 |
1955年 | 1篇 |
排序方式: 共有986条查询结果,搜索用时 546 毫秒
91.
92.
93.
94.
Computer and communications technologies are changing the way the world shares information. Renewable energy professionals should use these tools to their utmost advantage to exchange information, recapture “lost opportunities” in sustainable development, and create better designs for the new century and beyond. CREST, in partnership with the U.S. Department of Energy, Office of Energy Efficiency and Renewable Energy, and other federal and private agencies, is enabling such a future by creating innovative software tools and using online communications to foster the education, advancement and use of renewable energy and energy efficiency. 相似文献
95.
BACKGROUND: Sirolimus, a novel immunosuppressant that inhibits cytokine-driven cell proliferation and maturation, prolongs allograft survival in animal models. After a phase I trial in stable renal transplant recipients documented that cyclosporine and sirolimus have few overlapping toxicities, we conducted an open-label, single-center, phase I/II dose-escalation trial to examine the safety and efficacy of this drug combination. METHODS: Forty mismatched living-donor renal transplant recipients were sequentially assigned to receive escalating initial doses of sirolimus (0.5-7.0 mg/m2/day), in addition to courses of prednisone and a concentration-controlled regimen of cyclosporine. We conducted surveillance for drug-induced side effects among sirolimus-treated patients and compared their incidence of acute rejection episodes as well as mean laboratory values with those of a historical cohort of 65 consecutive, immediately precedent, demographically similar recipients treated with the same concentration-controlled regimen of cyclosporine and tapering doses of prednisone. RESULTS: The addition of sirolimus reduced the overall incidence of acute allograft rejection episodes to 7.5% from 32% in the immediately precedent cyclosporine/prednisone-treated patients. At 18- to 47-month follow-up periods, both treatment groups displayed similar rates of patient and graft survival, as well as morbid complications. Although sirolimus-treated patients displayed comparatively lower platelet and white blood cell counts and higher levels of serum cholesterol and triglycerides, sirolimus did not augment the nephrotoxic or hypertensive proclivities of cyclosporine. The degree of change in the laboratory values was more directly associated with whole blood trough drug concentrations than with doses of sirolimus. CONCLUSIONS: Sirolimus potentiates the immunosuppressive effects of a cyclosporine-based regimen by reducing the rate of acute rejection episodes. 相似文献
96.
RH Kerman B Susskind J Ruth S Katz CT Van Buren BD Kahan 《Canadian Metallurgical Quarterly》1998,66(12):1833-1834
Performance of the pretransplant crossmatch requires 4 or more hours . Delays in the crossmatch might alter operating room availability and thereby increase donor organ cold ischemia time that might then result in increased risk of delayed graft function. To avoid these problems, recipients could be identified who would be expected to display negative donor crossmatches and who could be transplanted with a concurrent or retrospective rather than a pretransplant crossmatch. We, therefore, evaluated the percent reactive antibodies and donor IgG-antihuman globulin (AHG) crossmatch results of 1165 sera from 220 potential allograft recipients. Twenty-five (11%) of 220 recipients consistently displayed a 0% PRA and, with only one exception, their sera (n= 156) tested IgG-AHG crossmatch-negative against potential cadaveric donors (a 0.6% IgG-AHG positive crossmatch risk). These data suggest that the timing of the pretransplant serum crossmatch could be altered for a highly selected group of immunologically nonreactive recipients. 相似文献
97.
98.
LA Farrer KS Arnos JH Asher CT Baldwin SR Diehl TB Friedman J Greenberg KM Grundfast C Hoth AK Lalwani 《Canadian Metallurgical Quarterly》1994,55(4):728-737
Waardenburg syndrome (WS) is a dominantly inherited and clinically variable syndrome of deafness, pigmentary changes, and distinctive facial features. Clinically, WS type I (WS1) is differentiated from WS type II (WS2) by the high frequency of dystopia canthorum in the family. In some families, WS is caused by mutations in the PAX3 gene on chromosome 2q. We have typed microsatellite markers within and flanking PAX3 in 41 WS1 kindreds and 26 WS2 kindreds in order to estimate the proportion of families with probable mutations in PAX3 and to study the relationship between phenotypic and genotypic heterogeneity. Evaluation of heterogeneity in location scores obtained by multilocus analysis indicated that WS is linked to PAX3 in 60% of all WS families and in 100% of WS1 families. None of the WS2 families were linked. In those families in which equivocal lod scores (between -2 and +1) were found, PAX3 mutations have been identified in 5 of the 15 WS1 families but in none of the 4 WS2 families. Although preliminary studies do not suggest any association between the phenotype and the molecular pathology in 20 families with known PAX3 mutations and in four patients with chromosomal abnormalities in the vicinity of PAX3, the presence of dystopia in multiple family members is a reliable indicator for identifying families likely to have a defect in PAX3. 相似文献
99.
100.
The percutaneous approach to retained biliary duct stones is most reasonable in the presence of a T-tube because of the low morbidity and mortality as well as its low cost. We report our experience with 373 patients, emphasizing the technique and the solutions to some frequent problems. 相似文献